Skip navigation
中文
English
DSpace
CRIS
首頁
單位
研究人員
研究成果檢索
分類瀏覽
單位
研究人員
研究成果檢索
學術出版
幫助
登入
中文
English
NTU Scholars
研究成果檢索
瀏覽 的方式: 作者
或是輸入前幾個字:
跳到:
0-9
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
排序方式:
升冪
降冪
結果/頁面
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
作者/紀錄:
全部
1
5
10
15
20
25
30
35
40
45
50
顯示 48 到 63 筆資料,總共 63 筆
< 上一頁
公開日期
標題
作者
來源出版物
scopus
WOS
全文
2017
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
SHENG-KAI LIANG
; MIN-SHU HSIEH
; MENG-RUI LEE
; LI-TA KENG
; JEN-CHUNG KO
; JIN-YUAN SHIH
Oncotarget
55
52
2015
Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells
JEN-CHANG KO
; Syu J.-J.; Chen J.-C.; Wang T.-J.; Chang P.-Y.; Chen C.-Y.; Jian Y.-T.; Jian Y.-J.; Lin Y.-W.
Basic and Clinical Pharmacology and Toxicology
22
15
2009
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells
JEN-CHUNG KO
; Wang L.-H.; Jhan J.-Y.; Ciou S.-C.; Hong J.-H.; Lin S.-T.; Lin Y.-W.
Lung Cancer
9
9
2008
Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells
JEN-CHUNG KO
; Hong J.-H.; Wang L.-H.; Cheng C.-M.; Ciou S.-C.; Lin S.-T.; Jheng M.-Y.; Lin Y.-W.
Molecular Cancer Therapeutics
38
35
2008
The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer
JEN-CHUNG KO
; Hong J.-H.; Wang L.-H.; Lin Y.-W.
Experimental Cell Research
14
14
2009
Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells
JEN-CHUNG KO
; Ciou S.-C.; Jhan J.-Y.; Cheng C.-M.; Su Y.-J.; Chuang S.-M.; Lin S.-T.; Chang C.-C.; Lin Y.-W.
Molecular Cancer Research
45
40
2016
Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression
JEN-CHUNG KO
; Zheng H.-Y.; Chen W.-C.; Peng Y.-S.; Wu C.-H.; Wei C.-L.; Chen J.-C.; Lin Y.-W.
Biochemical Pharmacology
10
10
2020
Seroprevalence of Aspergillus IgG and disease prevalence of chronic pulmonary aspergillosis in a country with intermediate burden of tuberculosis: a prospective observational study
MENG-RUI LEE
; Huang H.-L; LUN-CHE CHEN
; HUNG-CHIH YANG
; JEN-CHUNG KO
; Cheng M.-H; Chong I.-W; LI-NA LEE
; JANN-YUAN WANG
; Dimopoulos G.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
21
19
1994
Superior vena cava syndrome: Rapid histologic diagnosis by ultrasound-guided transthoracic needle aspiration biopsy
JEN-CHUNG KO
; PAN-CHYR YANG
; ANG YUAN
; Chang D.-B.; CHONG-JEN YU
; HUEY-DONG WU
; LI-NA LEE
; Kuo S.-H.; KWEN-TAY LUH
American Journal of Respiratory and Critical Care Medicine
21
11
2010
Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells
JEN-CHUNG KO
; Su Y.-J.; Lin S.-T.; Jhan J.-Y.; Ciou S.-C.; Cheng C.-M.; Lin Y.-W.
Biochemical Pharmacology
71
62
2014
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells
JEN-CHANG KO
; Chiu H.-C.; Syu J.-J.; Jian Y.-J.; Chen C.-Y.; Jian Y.-T.; Huang Y.-J.; Wo T.-Y.; Lin Y.-W.
Biochemical Pharmacology
26
25
2021
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
SHENG-KAI LIANG
; LI-TA KENG
; CHIA-HAO CHANG
; Wen, Yueh-Feng; MENG-RUI LEE
; CHING-YAO YANG
; JANN-YUAN WANG
; JEN-CHUNG KO
; JIN-YUAN SHIH
; CHONG-JEN YU
Frontiers in Oncology
2
3
2017
Tuberculosis contact investigation in an intermediate burden setting: Implications from a large tuberculosis contact cohort in Taiwan
MENG-RUI LEE
; CHENG-MAW HO
; Lee C.-H.; Lee M.-C.; LIH-YU CHANG
; KAI-LUN YU
; JEN-CHUNG KO
; JANN-YUAN WANG
; JANN-TAY WANG
; LI-NA LEE
European Respiratory Journal
17
15
1994
Ultrasonographic evaluation of peridiaphragmatic lesions: A prospective study
JEN-CHANG KO
; PAN-CHYR YANG
; Chang D.-B.; CHONG-JEN YU
; LI-NA LEE
; Kuo S.-H.; KWEN-TAY LUH
Journal of Medical Ultrasound
6
2011
Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells
JEN-CHUNG KO
; Tsai M.-S.; Chiu Y.-F.; Weng S.-H.; Kuo Y.-H.; Lin Y.-W.
Journal of Pharmacology and Experimental Therapeutics
19
20
2016
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
Pan, Chun-Hao; Chang, Ying-Fang; Lee, Ming-Shuo; Wen, B-Chen; JEN-CHUNG KO
; SHENG-KAI LIANG
; Liang, Mei-Chih
BMC cancer
35
32